Pharmaco - Press Releases

Date	Title	Company
23-Feb-2023	BioSenic optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment	BioSenic
23-Feb-2023	Applications for pharma jobs tumble prompting fears of a worsening talent crisis	APSCo
23-Feb-2023	Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)	Xspray Pharma
23-Feb-2023	OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology	OSE Immunotherapeutics
23-Feb-2023	Genmab Announces Initiation of Share Buy-Back Program	Genmab
23-Feb-2023	Genmab Publishes 2022 Annual Report	Genmab
23-Feb-2023	EVERSANA CONSULTING Named a Top Ranked Consulting Firm by Vault Across Asia Pacific	EVERSANA CONSULTING
23-Feb-2023	iOmx Therapeutics appoints Dr. Christine Rothe as new Chief Development Officer	iOmx Therapeutics AG
23-Feb-2023	: Biophytis To Host A Combined General Shareholder’s Meeting On March 30, 2023	Biophytis
23-Feb-2023	Gerresheimer AG: Gerresheimer 2022: Profitable growth company boosting revenue and adjusted EBITDA growth to double-digit levels	Gerresheimer AG
22-Feb-2023	Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration	Essex Bio-Technology Limited
22-Feb-2023	Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors	ABIVAX
22-Feb-2023	MODERNA AND LIFE EDIT THERAPEUTICS ENTER STRATEGIC COLLABORATION TO ACCELERATE THE DEVELOPMENT OF NOVEL IN VIVO GENE EDITING THERAPIES	MODERNA
22-Feb-2023	PHARMANOVIA ENTERS IN-LICENSING AGREEMENT WITH AXSOME THERAPEUTICS TO MARKET AND FURTHER DEVELOP SUNOSI® (SOLRIAMFETOL), A FIRST-IN-CLASS TREATMENT FOR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEOPLE WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNOEA	PHARMANOVIA
22-Feb-2023	NICE Publishes Reimbursement Recommendation for Translarna™	PTC Therapeutics, Ltd.
22-Feb-2023	Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)	Ferrer
22-Feb-2023	ViiV Healthcare receives EU Marketing Authorisation for Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV in Europe	ViiV Healthcare
22-Feb-2023	Mettler-Toledo to Host a Live Webinar on Glass in Glass X-ray Inspection	Mettler-Toledo
22-Feb-2023	eXmoor pharma and vaccine developer Imophoron sign process development partnership	eXmoor pharma
22-Feb-2023	Prof. Molly Stevens receives the Novo Nordisk Prize – Understanding how materials and biology interact has revolutionised healthcare technologies	Novo Nordisk Foundation